Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly, Incyte receive FDA approval for severe alopecia areata medicine
Olumiant is marked as the first and only systemic medicine for severe AA adult patients. It is an oral and once-daily JAK inhibitor which is available through specialty
Olumiant is marked as the first and only systemic medicine for severe AA adult patients. It is an oral and once-daily JAK inhibitor which is available through specialty
The collaboration will use ImmunoGen’s linker-payload technology which is directed to new targets that are identified by OBT through its OGAP discovery platform. The two companies will jointly
Under the terms of the deal, Bavarian Nordic will be responsible for the supply of 500,000 additional doses of Jynneos vaccines this year. Previously in 2020, the company
Under the deal, Aurigene will receive $8m of upfront licensing payment for rights to the company’s pre-existing programme. The company will also be eligible for up to $60m
The antibody is indicated to treat R/R FL patients who have received at least two prior systemic therapies. Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that targets
The regulatory approval has been granted for the therapy to treat moderate-to-severe atopic dermatitis in children whose disease is not controlled with topical prescription therapies or when they
The approval will increase MMR vaccine choices in the US. Priorix (Measles, Mumps and Rubella Vaccine, Live) can be given as two doses. It can also be administered
According to a company statement, sugemalimab was approved for use on unresectable stage III NSCLC patients without disease progression after concurrent or sequential platinum-based chemoradiotherapy. NMPA approved sugemalimab
OrbiMed and Maruho have jointly led the financing round, which has also seen participation from HBM Healthcare Investments, Access Biotechnology, TCG X, Omega Funds, Decheng Capital, Samsara BioCapital,
PreHevbri is said to be the only approved 3-antigen hepatitis B vaccine for adults in the UK. It comprises the three hepatitis B surface antigens, S, pre-S1, and